Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Capital Expenditures (2017 - 2025)

Sutro Biopharma's Capital Expenditures history spans 9 years, with the latest figure at $47000.0 for Q3 2025.

  • For Q3 2025, Capital Expenditures fell 94.32% year-over-year to $47000.0; the TTM value through Sep 2025 reached -$1.3 million, down 121.39%, while the annual FY2024 figure was $673000.0, 84.4% down from the prior year.
  • Capital Expenditures for Q3 2025 was $47000.0 at Sutro Biopharma, up from -$4000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $11.4 million in Q3 2021 and bottomed at -$2.2 million in Q3 2023.
  • The 5-year median for Capital Expenditures is $809000.0 (2021), against an average of $1.5 million.
  • The largest annual shift saw Capital Expenditures surged 553.14% in 2021 before it plummeted 400.68% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at $2.5 million in 2021, then skyrocketed by 32.72% to $3.4 million in 2022, then increased by 18.44% to $4.0 million in 2023, then plummeted by 134.03% to -$1.4 million in 2024, then soared by 103.46% to $47000.0 in 2025.
  • Per Business Quant, the three most recent readings for STRO's Capital Expenditures are $47000.0 (Q3 2025), -$4000.0 (Q2 2025), and $27000.0 (Q1 2025).